| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/27/2010 | EP2146959A1 Vanilloid receptor ligands and the use thereof for the production of pharmaceuticals |
| 01/27/2010 | EP2146731A1 New use for cannabinoid-containing plant extracts |
| 01/27/2010 | EP1924605B1 Compositions and methods for diagnosing and treating an inflammation |
| 01/27/2010 | EP1438298B1 Piperazine derivatives with ccr1 receptor antagonist activity |
| 01/27/2010 | EP1362106B1 Streptococcus pyogenes polypeptides and corresponding dna fragments |
| 01/27/2010 | CN101633645A N3 alkylated benzimidazole derivatives as mek inhibitors |
| 01/27/2010 | CN101633644A N3 alkylated benzimidazole derivatives as mek inhibitors |
| 01/27/2010 | CN101632669A Method of using diketopiperazines and composition containing them |
| 01/27/2010 | CN100584954C Method for producing paeonin metabolite-I by short lactobacillin fermentation |
| 01/27/2010 | CN100584843C Substituted diaza-spiro-[5.5|-undecane derivatives and their use as neurokinin antagonists |
| 01/27/2010 | CN100584841C Andrographolide derivatives and application of the same in pharmacy |
| 01/27/2010 | CN100584369C Composition of Chinese traditional medicine for treating rheumatism |
| 01/27/2010 | CN100584368C Medicine for treating rheumatoid and rheumatoid arthritis and its preparation method |
| 01/27/2010 | CN100584336C Medicinal compositions |
| 01/27/2010 | CN100584315C Nasal administration preparation containing bupleurum root volatile oil |
| 01/27/2010 | CN100584207C Agastache mate tea |
| 01/26/2010 | US7653495 Comprises series of steps including identifying cavity proximal to functional critical site, determining physical parameters of cavity, identifying functional groups which can be accommodated by cavity, testing compounds comprising such functional groups in an in vitro assay to determine which are active |
| 01/26/2010 | US7652144 Compounds as PDE IV and TNF inhibitors |
| 01/26/2010 | US7652141 Immunosuppressants, analgesics, antiinflammatory agents |
| 01/26/2010 | US7652054 Gastrointestinal disorders; cardiovascular disorders; dyspepsia;anticancer agents; antiulcer agents |
| 01/26/2010 | US7652044 P-38 inhibitors |
| 01/26/2010 | US7652035 CRF receptor antagonists and methods relating thereto |
| 01/26/2010 | US7652022 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; |
| 01/26/2010 | US7652019 5,6-trimethylenepyrimidin-4-one compounds |
| 01/26/2010 | US7652012 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide maleate and pharmaceutical compositions thereof |
| 01/26/2010 | US7652010 Azabicyclic aryl derivatives and their medical use |
| 01/26/2010 | US7651703 Comprising hyaluronic acid or sodium hyaluronate dissolved in physiological buffer at concentration of 0.01-3 percent weight per volume and particles comprising first component biologically active agent and second component biocompatible polymeric matrix; use of 23-gauge or smaller bore needle |
| 01/26/2010 | US7651700 Topical diclofenac patch |
| 01/26/2010 | US7651698 Prolonged release bioadhesive therapeutic systems |
| 01/26/2010 | US7651692 Skin disorders; cosmetics; aging resistance |
| 01/26/2010 | CA2481012C Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| 01/26/2010 | CA2471651C Amorphous substance of tricyclic triazolobenzazepine derivative |
| 01/26/2010 | CA2470064C Triazolo-quinolin derivatives useful as adenosine receptor ligands |
| 01/26/2010 | CA2447099C Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/26/2010 | CA2422889C Method for the treatment of neurological and neuropsychological disorders |
| 01/26/2010 | CA2421588C Tnf receptor-like molecules and uses thereof |
| 01/26/2010 | CA2383250C Phytochemicals for treatment of mastalgia and endometriosis |
| 01/26/2010 | CA2350031C N-arylsulfonylamino acid omega-amides |
| 01/26/2010 | CA2301499C T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof |
| 01/26/2010 | CA2222524C Somatostatin peptides |
| 01/26/2010 | CA2213500C Use of g class immunoglobulins for the topical treatment of atopic dermatitis |
| 01/21/2010 | WO2010009116A2 Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
| 01/21/2010 | WO2010009111A2 A drug depot implantable within a synovial joint |
| 01/21/2010 | WO2010009091A2 Anti-inflammatory and anti-allergy extracts from nettle |
| 01/21/2010 | WO2010009056A2 Pain relieving patch |
| 01/21/2010 | WO2010008843A1 Apoptosis signal-regulating kinase 1 inhibitors |
| 01/21/2010 | WO2010008084A1 Novel use application of sugar chain-recognizing receptor |
| 01/21/2010 | WO2010008001A1 Aptamer against il-17 and use thereof |
| 01/21/2010 | WO2010007972A1 Novel indole derivative having carbamoyl group, ureide group and substituted oxy group |
| 01/21/2010 | WO2010007944A1 Nitrogenated bicyclic heterocyclic compound |
| 01/21/2010 | WO2010007943A1 Nitrogenated heterocyclic compound |
| 01/21/2010 | WO2010007756A1 Pyridine derivative having ttk inhibition activity |
| 01/21/2010 | WO2010007427A1 Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases |
| 01/21/2010 | WO2010007252A2 Formulation for improving the bioavailability of a hydrophobic molecule |
| 01/21/2010 | WO2010007099A1 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| 01/21/2010 | WO2010007027A1 Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors |
| 01/21/2010 | WO2010006970A1 Novel phenylimidazopyrazines |
| 01/21/2010 | WO2010006947A1 Novel phenyl-imidazopyridines and pyridazines |
| 01/21/2010 | WO2010006772A2 Use of cd95 inhibitors for the treatment of inflammatory disorders |
| 01/21/2010 | WO2010006704A1 Oxazolopyrimidines as edg-1 receptor agonists |
| 01/21/2010 | WO2010006635A1 Treatment of inflammatory bowel disease |
| 01/21/2010 | WO2009149279A3 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| 01/21/2010 | WO2009129510A3 Sulindac formulations in a biodegradable material |
| 01/21/2010 | WO2009129433A3 Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
| 01/21/2010 | WO2009117710A3 Methods of treating inflammation |
| 01/21/2010 | WO2009112677A3 Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof |
| 01/21/2010 | WO2008156092A8 Azolylmethylidenehydrazine derivative and use thereof |
| 01/21/2010 | WO2008128045A8 Solid forms of (e) -1- (4- ( (1r, 2s, 3r) -1, 2, 3, 4-tetrahydroxybutyl) -1h-imidazol-2-yl)ethanone oxime |
| 01/21/2010 | WO2007041130A3 Deazapurines useful as inhibitors of janus kinases |
| 01/21/2010 | US20100016955 Triazole compounds and methods of making and using the same |
| 01/21/2010 | US20100016938 Diagnosing, monitoring and treating inflammation |
| 01/21/2010 | US20100016557 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 01/21/2010 | US20100016440 Alpha-aminoamide derivatives useful as anti-inflammatory agents |
| 01/21/2010 | US20100016432 Resolvins: biotemplates for novel therapeutic interventions |
| 01/21/2010 | US20100016391 Isoxazoline Compounds Having MIF Antagonist Activity |
| 01/21/2010 | US20100016388 Salts of a Selective Beta-2 Andrenoceptor Agonist |
| 01/21/2010 | US20100016386 Selective glycosidase inhibitors and uses thereof |
| 01/21/2010 | US20100016380 TNF-alpha production inhibitors |
| 01/21/2010 | US20100016370 Process for the preparation of esomeprazole magnesium in a stable form |
| 01/21/2010 | US20100016365 Substituted 4-amino-piperidines |
| 01/21/2010 | US20100016361 Aryl carboxylic acid cyclohexyl amide derivatives |
| 01/21/2010 | US20100016357 Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain |
| 01/21/2010 | US20100016344 Amino heterocyclic linked pyrimidine derivatives |
| 01/21/2010 | US20100016338 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents |
| 01/21/2010 | US20100016332 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 01/21/2010 | US20100016330 Novel Derivatives |
| 01/21/2010 | US20100016286 Anti-Inflammatory Agents |
| 01/21/2010 | US20100016274 Beta-lactam cannabinoid receptor modulators |
| 01/21/2010 | US20100016265 Anti-inflammatory composition and method for preparation |
| 01/21/2010 | US20100016262 Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis |
| 01/21/2010 | US20100016224 Compositions and methods for modulating an immune response |
| 01/21/2010 | US20100016216 Adiponectin and uses thereof |
| 01/21/2010 | US20100015254 Use of tea-derived, theaflavin enriched extract to increase exercise performance and reduce exercise recovery time |
| 01/21/2010 | US20100015237 NSAID Delivery from Polyarylates |
| 01/21/2010 | US20100015234 Pharmaceutical preparations and their manufacture |
| 01/21/2010 | US20100015196 Drug Depot Implantable Within a Joint |
| 01/21/2010 | US20100015162 treating interleukin-22 (IL-22)-associated disorder such as arthritis or psoriasis by administering the antibody in an amount sufficient to inhibit or reduce immune cell activity in the subject |
| 01/21/2010 | US20100015156 Diagnosis of inflammatory bowel disease in children |
| 01/21/2010 | US20100015145 Use of a compound for reducing the biological effectiveness of IL-6 |
| 01/21/2010 | US20100015130 Disc-1 pathway activators in the control of neurogenesis |